Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2

Neuroscience Letters

Volumn 454, Issue 3, 2009, Pages 229-232

  Yasumoto, Satoshi ^a,b   Tamura, Kohei ^a   Karasawa, Junichi ^a   Hasegawa, Ryota ^a   Ikeda, Kazutaka ^a   Yamamoto, Toshifumi ^a,b   Yamamoto, Hideko ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Dopamine; Fluoxetine; Synaptic vesicle; VMAT2

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADENOSINE TRIPHOSPHATASE; COCAINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; METHAMPHETAMINE; PAROXETINE; PHENCYCLIDINE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; SULTOPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ELECTRON MICROSCOPY; IN VITRO STUDY; KINETICS; MAJOR DEPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE;

ANIMALS; DOPAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAROXETINE; RATS; RATS, WISTAR; RESERPINE; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC VESICLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 63249100822     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.03.049     Document Type: Article

References (29)

1. Bogen I.L., Haug K.H., Myhre O., and Fonnum F. Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem. Int. 43 (2003) 393-400
2. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
3. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 100 (1990) 509-514
4. Crowley J.J., Brodkin E.S., Blendy J.A., Berrettini W.H., and Lucki I. Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 31 (2006) 2433-2442
5. Cubells J.F., Rayport S., Rajendran G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 (1994) 2260-2271
6. Darchen F., Scherman D., and Henry J.P. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28 (1989) 1692-1697
7. + uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br. J. Pharmacol. 109 (1993) 411-414
8. 3H]dopamine accumulation by synaptic vesicles purified from rat striatum: inhibition by thiocyanate ion. Brain Res. 516 (1990) 155-160
9. Fukui M., Rodriguiz R.M., Zhou J., Jiang S.X., Phillips L.E., Caron M.G., and Wetsel W.C. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J. Neurosci. 27 (2007) 10520-10529
10. 3H]serotonin. Life Sci. 56 (1995) 785-791
11. 3H]serotonin. Naunyn Schmiedebergs Arch. Pharmacol. 345 (1992) 1-6
12. Henry J.P., Botton D., Sagne C., Isambert M.F., Desnos C., Blanchard V., Raisman-Vozari R., Krejci E., Massoulie J., and Gasnier B. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. J. Exp. Biol. 196 (1994) 251-262
13. Henry J.P., and Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol. 38 (1989) 2395-2404
14. Henry M.E., Moore C.M., Kaufman M.J., Michelson D., Schmidt M.E., Stoddard E., Vuckevic A.J., Berreira P.J., Cohen B.M., and Renshaw P.F. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am. J. Psychiatry 157 (2000) 1506-1508
15. Heurteaux C., Lucas G., Guy N., El Yacoubi M., Thummler S., Peng X.D., Noble F., Blondeau N., Widmann C., Borsotto M., Gobbi G., Vaugeois J.M., Debonnel G., and Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat. Neurosci. 9 (2006) 1134-1141
16. Kelly R.B. Storage and release of neurotransmitters. Cell 72 Suppl. (1993) 43-53
17. Kennard L.E., Chumbley J.R., Ranatunga K.M., Armstrong S.J., Veale E.L., and Mathie A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 144 (2005) 821-829
18. Merickel A., Rosandich P., Peter D., and Edwards R.H. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270 (1995) 25798-25804
19. Moriyama Y., Tsai H.L., and Futai M. Energy-dependent accumulation of neuron blockers causes selective inhibition of neurotransmitter uptake by brain synaptic vesicles. Arch. Biochem. Biophys. 305 (1993) 278-281
20. Scherman D., and Henry J.P. Effect of drugs on the ATP-induced and pH-gradient-driven monoamine transport by bovine chromaffin granules. Biochem. Pharmacol. 29 (1980) 1883-1890
21. Scherman D., and Henry J.P. Reserpine binding to bovine chromaffin granule membranes: characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25 (1984) 113-122
22. Schmalzing G. The role of a transmembrane pH gradient in uptake and release of imipramine and haloperidol in synaptosomes. Mol. Pharmacol. 34 (1988) 888-895
23. Staal R.G., Hogan K.A., Liang C.L., German D.C., and Sonsalla P.K. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 293 (2000) 329-335
24. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 (1995) 4102-4108
25. 3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280 (1997) 1432-1444
26. Thummler S., Duprat F., and Lazdunski M. Antipsychotics inhibit TREK but not TRAAK channels. Biochem. Biophys. Res. Commun. 354 (2007) 284-289
27. Varoqui H., and Erickson J.D. Vesicular neurotransmitter transporters: potential sites for the regulation of synaptic function. Mol. Neurobiol. 15 (1997) 165-191
28. Zubieta J.K., Taylor S.F., Huguelet P., Koeppe R.A., Kilbourn M.R., and Frey K.A. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol. Psychiatry 49 (2001) 110-116
29. Zucker M., Aviv A., Shelef A., Weizman A., and Rehavi M. Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression. Psychiatry Res. 112 (2002) 251-256